2016 年第 12 期 第 14 卷

血清_EB-VCA-IgA_、EA-D-IgA和EA-D-IgG抗体对鼻咽癌诊断的意义

作者：

单位：

关键词：鼻咽癌EB病毒免疫球蛋白抗体

• 摘要：
• 【摘要】目的 探讨鼻咽癌患者血清EB病毒壳抗原（VCA）免疫球蛋白A（VCA-IgA）、EB病毒早期抗原-D-IgA抗体（EA-D-IgA）、EA-D-IgG联合检测对于鼻咽癌患者诊断的价值。方法 选取60例经病理学确诊的鼻咽癌患者（鼻咽癌组）、60例良性鼻咽疾病患者（良性组），采用酶联免疫吸附法（ELISA）检测血清VCA-IgA、EA-D-IgA、EA-D-IgG，对比两组患者的检出阳性率，并计算相关诊断学效能指标。结果 鼻咽癌组血清VCA-IgA、EA-D-IgA、EA-D-IgG抗体阳性率分别为81.67%、50.00%、83.33%均显著的高于良性组的10.00%、5.00%、3.33%，差异均具有统计学意义（P<0.05）；血清VCA-IgA鉴别诊断鼻咽癌的灵敏度为81.67%、特异度为86.67%；EA-D-IgA鉴别诊断鼻咽癌的灵敏度为48.33%、特异度为91.67%；EA-D-IgG鉴别诊断鼻咽癌的灵敏度为83.33%、特异度为88.33%；血清VCA-IgA+EA-D-IgA+EA-D-IgG鉴别诊断鼻咽癌的灵敏度为95.00%、特异度为96.67%。结论 鼻咽癌患者血清VCA-IgA+EA-D-IgA+EA-D-IgG对于提高鼻咽癌诊断具有更高的临床价值
• ObjectiveTo investigate the value of serum EB virus capsid antigen (VCA) immunoglobulin A (VCA-IgA), EB virus early antigen -D-IgA antibody (EA-D-IgA) and EA-D-IgG combined detection in the diagnosis of nasopharyngeal carcinoma patients. Methods A total of 60 cases of patients with nasopharyngeal carcinoma diagnosed by pathology (NPC group), 60cases of benign nasopharyngeal diseases (benign group), using enzyme-linked immunosorbent assay (ELISA) detection of serum VCA-IgA, EA-D-IgA, EA-D-IgG, compared two groups of patients with positive rate, and calculate the relevant diagnostic effectiveness index. Results Nasopharyngeal carcinoma group serum VCA-IgA, EA-D-IgA, EA-D-IgG antibody positive rates were 81.67%, 50% and 83.33% were significantly higher than that in benign group 10%, 5%, 3.33%, the differences were statistically significant (P<0.05); the sensitivity of serum VCA-IgA in differential diagnosis of nasopharyngeal carcinoma was 81.67%, the specificity was 86.67%; the sensitivity of EA-D-IgA was 48.33%, the differential diagnosis of nasopharyngeal carcinoma the specificity was 91.67%; the sensitivity of EA-D-IgG in diagnosis and differential diagnosis of nasopharyngeal carcinoma was 83.33%, the specificity was 88.33%; the sensitivity of serum VCA-IgA+EA-D-IgA+EA-D-IgG in differential diagnosis of nasopharyngeal carcinoma was 95%, specificity was 96.67%. Conclusion The serum VCA-IgA+EA-D-IgA+EA-D-IgG in patients with nasopharyngeal carcinoma has higher clinical value in the diagnosis of nasopharyngeal carcinoma.